将PCSK9抑制剂添加到降脂干预措施对动脉硬度的影响:系统性审查和元分析
I Cavero-Redondo1,2, N Moreno-Herraiz1, A Del Saz-Lara1,3,4
1CarVasCare Research Group (2023-GRIN-34459), Faculta de Enfermería de Cuenca, Universidad de Castilla-La Mancha, Cuenca, Spain.
European journal of clinical investigation
|July 20, 2024
概括
蛋白转化酶亚素/素9型抑制剂 (PCSK9i) 显著改善了除了降低LDL-C之外的动脉硬性. 这一发现表明,血管对心血管健康有更广泛的血管益处.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血管生物学 血管生物学
背景情况:
- 动脉样硬化症的治疗需要控制高胆固醇血症,特别是增加的LDL-C.
- 蛋白转化酶亚素/素9型抑制剂 (PCSK9i) 已经彻底改变了降脂疗法.
- 超出脂质降低,PCSK9i对动脉健康的潜在类作用,需要调查.
研究的目的:
- 系统地审查和分析PCSK9i对动脉硬性的影响.
- 评估PCSK9i对血管健康的影响,超出传统的降脂指标.
- 为全面了解心血管风险降低策略做出贡献.
主要方法:
- 在数据库,试验注册表和灰色文献中进行系统的文献搜索.
- 包括接受PCSK9i治疗的成年人前性队列研究.
- 通过使用随机效应元分析和元回归测量脉冲波速度 (PWv) 的动脉硬度的分析.
主要成果:
- 有158名参与者的5项研究符合标准.
- 随着PCSK9i的添加,观察到PWv的显著降低 (平均差异:-2.61 m/s).
- 亚组分析表明基于性别和基线PWv的潜在变化.
结论:
- 将PCSK9i添加到降脂干预措施中可以显著改善动脉硬.
- PCSK9i表明血管效益超出了降低LDL-C的范围.
- 这些发现支持PCSK9i在心血管风险管理中的更广泛作用.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
621
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
621
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
143
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
143
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Antihypertensive Drugs: Vasodilators
497
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
497
Antihypertensive Drugs: Action of Calcium Channel Blockers
489
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
489


